← All organizations
First clinical trial
Jan 1, 2003Last known activity
Apr 1, 2015
Acquired by Madrigal Pharmaceuticals on Apr 14, 2016
Timeline
2000s
- Jun 1, 2000
Synta Pharmaceuticals Corp.— Founded
2010s
- Apr 14, 2016
Madrigal Pharmaceuticals— Acquired By
Drugs by trial phase (14 distinct, 39 trials)
Phase 3 (4 own, 0 via acquisition)
Phase 2 (4 own, 0 via acquisition)
Phase 1 (6 own, 0 via acquisition)
Indications
Studied for
- Adenocarcinoma
- Adenocarcinoma of Lung
- Arthritis
- Arthritis, Rheumatoid
- Blast Crisis
- Breast Neoplasms
- Breast Neoplasms, Male
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Squamous Cell
- Colonic Neoplasms
- Crohn Disease
- Esophageal Neoplasms
- Gastrointestinal Stromal Tumors
- Leukemia
- Leukemia, Lymphoid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lung Neoplasms
- Melanoma
- Multiple Myeloma
- Myeloproliferative Disorders
- Neoplasms
- Neoplasms, Plasma Cell
- Nerve Sheath Neoplasms
- Neurofibrosarcoma
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Prostatic Neoplasms
- Rectal Neoplasms
- Sarcoma
- Small Cell Lung Carcinoma
- Triple Negative Breast Neoplasms
Recent trials (39)
- NCT02389751CollaboratorPhase 1Apr 1, 2015
- NCT02334319CollaboratorPhase 1Dec 1, 2014
- NCT02261805CollaboratorPhase 1/Phase 2Oct 1, 2014
- NCT02060253CollaboratorPhase 1Apr 1, 2014
- NCT02008877CollaboratorPhase 1/Phase 2Dec 1, 2013
- NCT01798485Lead sponsorPhase 3Apr 1, 2013
- NCT01677455Lead sponsorPhase 2Jul 1, 2012
- NCT01554969CollaboratorPhase 1May 1, 2012
- NCT01562015Lead sponsorPhase 2Apr 1, 2012
- NCT01485835CollaboratorPhase 1Jan 1, 2012
- NCT01551693CollaboratorPhase 2Sep 1, 2011
- NCT01348126Lead sponsorPhase 2/Phase 3May 1, 2011
- NCT01273896CollaboratorPhase 2Jan 1, 2011
- NCT01280786Lead sponsorPhase 1Jan 1, 2011
- NCT01167114CollaboratorPhase 2Aug 1, 2010
Details
- Founded
- Lexington, MA, US Jun 1, 2000
- Last known activity
- Apr 1, 2015